Study Immunotherapy and Chemotherapy Before Colon Surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent and follow the study plan.
- Your colon tumor is confirmed to be resectable (can be surgically removed) and non-metastatic (no distant spread).
- Your tumor test shows MSS or pMMR (based on lab testing at the study site).
- Tumor is at least 12 cm above the anus (so it’s not treated like a rectal cancer).
- You have at least one “high-risk” feature (like higher CEA, certain lab ratios, or specific scan/pathology findings).
- Your general health and blood/organ tests meet study limits (including good performance status 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This trial tests whether a stronger chemo combination plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemo alone when given before surgery for locally advanced colon cancer. It aims to shrink the tumor and improve outcomes.
Hear when a new Stage I Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.